Journal of Clinical and Cellular Immunology : Citations & Metrics Report
Articles published in Journal of Clinical and Cellular Immunology have been cited by esteemed scholars and scientists all around the world. Journal of Clinical and Cellular Immunology has got h-index 42, which means every article in Journal of Clinical and Cellular Immunology has got 42 average citations.
Following are the list of articles that have cited the articles published in Journal of Clinical and Cellular Immunology.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total published articles |
30 | 31 | 30 | 59 | 28 | 11 | 35 | 56 | 95 | 105 | 101 | 105 | 64 | 15 | 3 |
Research, Review articles and Editorials |
2 | 13 | 8 | 23 | 18 | 8 | 25 | 35 | 54 | 86 | 79 | 35 | 23 | 14 | 3 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
20 | 18 | 22 | 22 | 10 | 3 | 10 | 21 | 39 | 6 | 9 | 7 | 1 | 1 | 0 |
Conference proceedings |
0 | 16 | 15 | 6 | 0 | 98 | 178 | 206 | 171 | 160 | 195 | 156 | 74 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
653 | 826 | 931 | 1079 | 1018 | 971 | 871 | 851 | 753 | 550 | 276 | 145 | 43 | 40 | 0 |
| Journal total citations count | 8361 |
| Journal impact factor | 24.12 |
| Journal 5 years impact factor | 31.14 |
| Journal cite score | 30.45 |
| Journal h-index | 42 |
| Journal h-index since 2019 | 32 |
Important citations (1511)
Sharquie ke, noaimi aa, burhan zt(2016) the frequency of skin tumors and infections in patients with autoimmune diseases. kidney 5: 14. |
|
Roy a, shankarmurthy sp. discoid lupus erythematosus at the vermilion border of the lip: a rare clinical presentation. |
|
Atassi mz, casali p (2015) analysis: autoimmune disorders: an overview of molecular and cellular basis in today’s perspective. j clin cell immunol 6: 302. |
|
Ostrov be (2015) immunotherapeutic biologic agents in autoimmune and autoinflammatory diseases. immunological investigations 44: 777-802. |
|
Mastrandrea ld (2015) an overview of organ-specific autoimmune diseases including immunotherapy. immunological investigations 44: 803-816. |
|
Vojdani a (2014) a potential link between environmental triggers and autoimmunity. autoimmune diseases 2014. |
|
Thobias ib, mujawar s, pardeshi t, chaudhary s, batra m, rao sp, deshmukh kb, raje s. identification of novel inhibitors for systemic lupus erythematosus by targeting ifn-α and fcγr2a: a structure based pharmacophore approach. |
|
Greth w, robbie gj, brohawn p, hultquist m, yao b (2017) targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus. immunotherapy 9: 57-70. |
|
Afzal n, shehzad f, rasheed s (2014)systemic lupus erythematosus–an immunological disorder: clinical presentations and therapeutic options. biomedica 30: 1. |
|
Lorenzo pérez n. a modified peptide ligand derived from the human 60 kda cellular stress protein with therapeutic effect in experimental models of autoimmune arthritis (doctoral dissertation). |
|
Manso vargas aa. evaluation of cell response induced by cigb 814 peptide in patients with rheumatoid arthritis in the phase 1 clinical trial (doctoral dissertation). |
|
Eve r, istvan varkonyi sz, zoltan s. pneumococcal infections and their prevention: vaccination update rheumatic autoimmune diseases. |
|
Argentina a. farmacoeconomÃa de la esclerosis múltiple. |
|
Millán pascual j. papel de los polimorfismos de los genes hemo-oxigenasa 1 y 2 en el riesgo de desarrollo de esclerosis múltiple. |
|
Ochi h (2014). mechanism of multiple sclerosis based on the clinical trial results of molecular targeted therapy. clinical and experimental neuroimmunology 5:6-15. |
|
Gross cc, schulte-mecklenbeck a, wiendl h, marcenaro e, de rosbo nk, et al.(2016) regulatory functions of natural killer cells in multiple sclerosis. frontiers in immunology 7. |
|
Geisler ch, tadmor t, polliack a (2015). treating chronic lymphocytic leukemia with a combination of rituximab and alemtuzumab: a “successful couple,†but are they still relevant together?. leukemia & lymphoma 56:275-6. |
|
Stevenson ev, mcgee j, alexander js, minagar a (2015) novel therapies for multiple sclerosis: a mechanistic view. multiple sclerosis: a mechanistic view 9:13. |
|
Wootla b, watzlawik jo, stavropoulos n, wittenberg nj, dasari h, et al. (2016) recent advances in monoclonal antibody therapies for multiple sclerosis. expert opinion on biological therapy 16:827-39. |
|
Willis m, pearson o, illes z, sejbaek t, nielsen c, et al. (2017) an observational study of alemtuzumab following fingolimod for multiple sclerosis. neurology-neuroimmunology neuroinflammation 4:e320. |
|